Literature DB >> 19022250

Increased alpha-synuclein aggregation following limited cleavage by certain matrix metalloproteinases.

Johannes Levin1, Armin Giese, Kai Boetzel, Lars Israel, Tobias Högen, Georg Nübling, Hans Kretzschmar, Stefan Lorenzl.   

Abstract

Recent evidence indicates that protein aggregation and in particular the formation of toxic protein oligomers is a key mechanism in synucleinopathies such as Parkinson's disease (PD). Post mortem brain tissue studies as well as animal studies furthermore suggest that matrix metalloproteinases (MMPs) are also involved in the pathogenesis of PD. We used confocal single molecule spectroscopy to characterize the influence of MMPs and other proteases on the aggregation of alpha-synuclein. These studies were complemented by the characterization of alpha-synuclein fragment patterns generated by these proteases using gel electrophoresis and mass spectrometry. Limited digestion by MMP-1 and MMP-3, but not by MMP-9, increased the tendency of alpha-synuclein to aggregate. Proteinase K and Trypsin did not increase the level of de novo aggregation of alpha-synuclein. SDS-PAGE as well as MALDI-ToF analysis of limitedly digested alpha-synuclein demonstrate that all proteases generate different fragments of alpha-synuclein. We provide mass spectrometry data of proteolytic alpha-synuclein fragments and propose specific cleavage sites for MMP-1 and MMP-9 in alpha-synuclein. We furthermore found four additional cleavage sites of MMP-3 that had not been described previously. In order to increase aggregation of alpha-synuclein, specific cleavage between the highly charged C-terminal domain and the aggregation-prone NAC domain of alpha-synuclein seems to be crucial. Our findings obtained in vitro in a well-characterized model of pathological alpha-synuclein aggregation indicate that MMP-1 and MMP-3 may also influence pathogenesis of PD in vivo by generation of specific aggregation-enhancing alpha-synuclein fragments resulting from limited proteolysis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19022250     DOI: 10.1016/j.expneurol.2008.10.010

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  33 in total

Review 1.  Cell Biology and Pathophysiology of α-Synuclein.

Authors:  Jacqueline Burré; Manu Sharma; Thomas C Südhof
Journal:  Cold Spring Harb Perspect Med       Date:  2018-03-01       Impact factor: 6.915

Review 2.  PMEL: a pigment cell-specific model for functional amyloid formation.

Authors:  Brenda Watt; Guillaume van Niel; Graça Raposo; Michael S Marks
Journal:  Pigment Cell Melanoma Res       Date:  2013-02-19       Impact factor: 4.693

Review 3.  Physiological functions and clinical implications of the N-end rule pathway.

Authors:  Yujiao Liu; Chao Liu; Wen Dong; Wei Li
Journal:  Front Med       Date:  2016-09-07       Impact factor: 4.592

Review 4.  The emerging role of α-synuclein truncation in aggregation and disease.

Authors:  Zachary A Sorrentino; Benoit I Giasson
Journal:  J Biol Chem       Date:  2020-05-18       Impact factor: 5.157

Review 5.  Metalloproteinases and their tissue inhibitors in Alzheimer's disease and other neurodegenerative disorders.

Authors:  Santiago Rivera; Laura García-González; Michel Khrestchatisky; Kévin Baranger
Journal:  Cell Mol Life Sci       Date:  2019-06-13       Impact factor: 9.261

6.  Proteolytic cleavage of extracellular α-synuclein by plasmin: implications for Parkinson disease.

Authors:  Kwang Soo Kim; Yu Ree Choi; Ji-Young Park; Jung-Ho Lee; Dong Kyu Kim; Seung-Jae Lee; Seung R Paik; Ilo Jou; Sang Myun Park
Journal:  J Biol Chem       Date:  2012-05-22       Impact factor: 5.157

Review 7.  Combination therapies: The next logical Step for the treatment of synucleinopathies?

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Mov Disord       Date:  2015-09-21       Impact factor: 10.338

8.  Neurodegeneration-associated protein fragments as short-lived substrates of the N-end rule pathway.

Authors:  Christopher S Brower; Konstantin I Piatkov; Alexander Varshavsky
Journal:  Mol Cell       Date:  2013-03-14       Impact factor: 17.970

9.  Axonopathy in an α-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated α-synuclein.

Authors:  Dora Games; Peter Seubert; Edward Rockenstein; Christina Patrick; Margarita Trejo; Kiren Ubhi; Benjamin Ettle; Majid Ghassemiam; Robin Barbour; Dale Schenk; Silke Nuber; Eliezer Masliah
Journal:  Am J Pathol       Date:  2013-01-09       Impact factor: 4.307

Review 10.  Function and dysfunction of α-synuclein: probing conformational changes and aggregation by single molecule fluorescence.

Authors:  Adam J Trexler; Elizabeth Rhoades
Journal:  Mol Neurobiol       Date:  2012-09-16       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.